Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD.
Presentation Details:
CRI-ENCI Eighth International Cancer Immunotherapy Conference
Title: Pre-clinical characterization of monoclonal antibodies targeting CD39 activity in the acidic tumor microenvironment
Presenter: F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early Development
Poster Number: 195A
Date and time: Sunday, September 8, 2024, 12:05 – 2:05 p.m. EDT
